KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EPS (Basic): 2018-2025

Historic EPS (Basic) for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -$0.16.

  • Esperion Therapeutics' EPS (Basic) fell 6.67% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.54, marking a year-over-year increase of 12.90%. This contributed to the annual value of -$0.28 for FY2024, which is 86.21% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' EPS (Basic) is -$0.16, which was down 166.67% from -$0.06 recorded in Q2 2025.
  • Esperion Therapeutics' EPS (Basic)'s 5-year high stood at $0.36 during Q1 2024, with a 5-year trough of -$3.50 in Q1 2021.
  • Its 3-year average for EPS (Basic) is -$0.25, with a median of -$0.21 in 2025.
  • In the last 5 years, Esperion Therapeutics' EPS (Basic) skyrocketed by 145.57% in 2024 and then crashed by 158.33% in 2025.
  • Quarterly analysis of 5 years shows Esperion Therapeutics' EPS (Basic) stood at -$1.53 in 2021, then spiked by 51.63% to -$0.74 in 2022, then soared by 32.43% to -$0.50 in 2023, then surged by 78.00% to -$0.11 in 2024, then dropped by 6.67% to -$0.16 in 2025.
  • Its last three reported values are -$0.16 in Q3 2025, -$0.06 for Q2 2025, and -$0.21 during Q1 2025.